Literature DB >> 15117881

Aggregation and lack of secretion of most newly synthesized proinsulin in non-beta-cell lines.

Yong Lian Zhu1, Alexander Abdo, Joan F Gesmonde, Kathleen C Zawalich, Walter Zawalich, Priscilla S Dannies.   

Abstract

Myoblasts transfected with HB10D insulin secrete more hormone than those transfected with wild-type insulin, as published previously, indicating that production of wild-type insulin is not efficient in these cells. The ability of non-beta-cells to produce insulin was examined in several cell lines. In clones of neuroendocrine GH(4)C(1) cells stably transfected with proinsulin, two thirds of (35)S-proinsulin was degraded within 3 h of synthesis, whereas (35)S-prolactin was stable. In transiently transfected neuroendocrine AtT20 cells, half of (35)S-proinsulin was degraded within 3 h after synthesis, whereas (35)S-GH was stable. In transiently transfected fibroblast COS cells, (35)S-proinsulin was stable for longer, but less than 10% was secreted 8 h after synthesis. Proinsulin formed a concentrated patch detected by immunofluorescence in transfected cells that did not colocalize with calreticulin or BiP, markers for the endoplasmic reticulum, but did colocalize with membrin, a marker for the cis-medial Golgi complex. Proinsulin formed a Lubrol-insoluble aggregate within 30 min after synthesis in non-beta-cells but not in INS-1E cells, a beta-cell line that normally produces insulin. More than 45% of (35)S-HB10D proinsulin was secreted from COS cells 3 h after synthesis, and this mutant formed less Lubrol-insoluble aggregate in the cells than did wild-type hormone. These results indicate that proinsulin production from these non-beta-cells is not efficient and that proinsulin aggregates in their secretory pathways. Factors in the environment of the secretory pathway of beta-cells may prevent aggregation of proinsulin to allow efficient production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117881     DOI: 10.1210/en.2003-1512

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes.

Authors:  Jinhong Sun; Jingqiu Cui; Qing He; Zheng Chen; Peter Arvan; Ming Liu
Journal:  Mol Aspects Med       Date:  2015-01-08

2.  Proinsulin intermolecular interactions during secretory trafficking in pancreatic β cells.

Authors:  Leena Haataja; Erik Snapp; Jordan Wright; Ming Liu; Alexandre B Hardy; Michael B Wheeler; Michele L Markwardt; Mark Rizzo; Peter Arvan
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

Review 3.  Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes.

Authors:  Anoop Arunagiri; Leena Haataja; Corey N Cunningham; Neha Shrestha; Billy Tsai; Ling Qi; Ming Liu; Peter Arvan
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

Review 4.  Proinsulin and the genetics of diabetes mellitus.

Authors:  Michael A Weiss
Journal:  J Biol Chem       Date:  2009-04-24       Impact factor: 5.157

Review 5.  Diabetes mellitus due to the toxic misfolding of proinsulin variants.

Authors:  Michael A Weiss
Journal:  FEBS Lett       Date:  2013-05-10       Impact factor: 4.124

6.  Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted.

Authors:  Soo-Young Park; Honggang Ye; Donald F Steiner; Graeme I Bell
Journal:  Biochem Biophys Res Commun       Date:  2009-12-23       Impact factor: 3.575

Review 7.  Structural Lessons From the Mutant Proinsulin Syndrome.

Authors:  Balamurugan Dhayalan; Deepak Chatterjee; Yen-Shan Chen; Michael A Weiss
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.